Welcome to our dedicated page for MBX Biosciences news (Ticker: MBX), a resource for investors and traders seeking the latest updates and insights on MBX Biosciences stock.
MBX Biosciences, Inc. (Nasdaq: MBX) is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, and its news flow reflects progress across multiple clinical programs and corporate initiatives. Company press releases and investor updates highlight developments from its proprietary Precision Endocrine Peptide™ (PEP™) platform, including clinical data, trial milestones, and financing activities.
News for MBX often centers on its lead candidates canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291. Coverage includes topline and follow-up results from the Phase 2 Avail™ trial of once-weekly canvuparatide in chronic hypoparathyroidism, initiation and progress of the Phase 2a STEADI™ trial of imapextide for post-bariatric hypoglycemia, and design and enrollment updates for the Phase 1 trial of MBX 4291 as a GLP-1/GIP co-agonist prodrug for obesity. MBX also issues releases on expected data readouts, planned regulatory interactions, and preparation for Phase 3 development.
Investors following MBX news will also see announcements related to public equity offerings, cash runway disclosures, and participation in major healthcare and investor conferences such as the J.P. Morgan Healthcare Conference and various cardiometabolic and obesity-focused forums. These items provide context on how the company funds its pipeline and communicates its strategy to the market.
This news page aggregates such updates so readers can track MBX’s clinical milestones, pipeline expansion in obesity, and key regulatory and financing events in one place. For those monitoring MBX stock or the broader endocrine and metabolic drug development space, the feed offers an organized view of how the company reports its progress over time.
MBX Biosciences (Nasdaq: MBX) has completed enrollment for its Phase 2 Avail™ trial of MBX 2109 (canvuparatide), surpassing the initial target of 48 patients with 64 enrollees. The trial evaluates a long-acting parathyroid hormone peptide prodrug for treating chronic hypoparathyroidism (HP).
The study is a randomized, multicenter, 12-week, double-blind, placebo-controlled trial assessing safety, pharmacokinetics, and efficacy. The primary endpoint focuses on patients' ability to discontinue active vitamin D and reduce calcium supplements while maintaining normal serum albumin-adjusted calcium levels. Secondary endpoints include safety, tolerability, pharmacodynamic activity, and quality of life measures.
Topline results are expected in Q3 2025. The company believes canvuparatide could transform HP treatment by providing more consistent therapeutic effects and improved patient convenience.
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in two major investor conferences in March 2025.
The company's President and CEO, Kent Hawryluk, will deliver a podium presentation at the TD Cowen 45th Annual Healthcare Conference in Boston on March 3, 2025, from 10:30-11:00 a.m. ET, along with one-on-one meetings. Additionally, MBX will participate in the Jefferies Biotech on the Beach Summit in Miami Beach on March 12th, featuring one-on-one meetings.
Webcasts of the presentations will be available on the investors section of MBX Biosciences' website, with replay access available approximately two hours post-event and archived for roughly 90 days.
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in three major investor conferences in February 2025.
The company's President and CEO, Kent Hawryluk, will participate in:
- A fireside chat at the Guggenheim SMID Cap Biotechnology Conference on February 5, 2025 (2:00-2:25 p.m. EST) in New York
- A panel presentation at the BIO CEO & Investor Conference on February 10, 2025 (11:00 a.m.-12:00 p.m. EST) in New York
- A podium presentation at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025 (8:40-9:10 a.m. EST)
Live webcasts will be available on the MBX Biosciences investor website, with replay access available for approximately 90 days after each event.
MBX Biosciences (Nasdaq: MBX) announced positive Phase 1 results for MBX 1416, their investigational long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia (PBH) treatment. The trial, involving 69 healthy volunteers, demonstrated that MBX 1416 was generally well-tolerated with a favorable safety profile.
Key findings include:
- No dose-related serious adverse events observed
- 90-hour median half-life supporting once-weekly dosing
- Dose-proportional concentration increases in both single and multiple ascending dose cohorts
- Increased GLP-1 levels within 60 minutes of meal tests
The company plans to initiate Phase 2 studies in PBH patients in the second half of 2025, pending FDA alignment at a mid-2025 End-of-Phase 1 meeting.
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Kent Hawryluk, President and CEO, will deliver a presentation on January 14th, 2025, at 2:15 p.m. Pacific Time.
The company will engage in one-on-one investor meetings during the conference. A live webcast will be available through the investors section of MBX Biosciences' website, with replay access provided approximately two hours after the event and remaining accessible for about 30 days.
MBX Biosciences published Phase 1 study results of MBX 2109, their parathyroid hormone peptide prodrug for hypoparathyroidism treatment, in The Journal of Clinical Endocrinology and Metabolism. The multiple ascending dose study involved 40 participants receiving four once-weekly subcutaneous doses. Key findings showed long half-lives (79-95 hours for prodrug, 184-213 hours for active drug), flat exposure profiles, and dose-proportional increases in serum calcium. The treatment was generally well-tolerated with mostly mild adverse events. The company expects to complete Phase 2 Avail™ trial enrollment in Q1 2025 with topline results in Q3 2025.
MBX Biosciences announced the completion of the last subject's last visit in its Phase 1 trial of MBX 1416, a long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia (PBH) treatment. The randomized, double-blind, placebo-controlled study enrolled 69 participants to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses in healthy adults. The company expects to release topline results in early January 2025. The trial represents a significant milestone in developing a treatment for PBH, a condition currently without approved therapies.
MBX Biosciences reported Q3 2024 financial results, highlighting a successful transition to public trading and advancement of clinical programs. The company raised $251.2 million through an IPO and Series C financing, with $277.1 million in cash expected to fund operations into mid-2027. Key developments include anticipated completion of MBX 1416 Phase 1 trial by late November with topline results in January 2025, and ongoing Phase 2 Avail™ trial of MBX 2109 for hypoparathyroidism expected to complete enrollment in Q1 2025. Q3 financial results showed R&D expenses of $16.7 million and a net loss of $18.1 million.
MBX Biosciences (NASDAQ: MBX), a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, has announced its participation in three major investor conferences in November 2024. The company will attend the Guggenheim Inaugural Healthcare Innovation Conference in Boston (Nov 12), the Stifel 2024 Healthcare Conference in New York (Nov 18), and the Jefferies London Healthcare Conference (Nov 20). Each session will feature either a fireside chat or company presentation format. Live webcasts will be available on the MBX Biosciences investor website, with replays accessible for approximately 90 days after each event.
MBX Biosciences presented the design and rationale of its Phase 2 Avail™ trial for MBX 2109, a potential long-acting parathyroid hormone (PTH) peptide prodrug, at the ASBMR 2024 Annual Meeting. The trial targets adults with hypoparathyroidism (HP) and aims to normalize serum calcium levels, reduce the need for vitamin D and calcium supplements, and improve patient convenience. The Phase 2 trial is a 12-week, double-blind, placebo-controlled study involving 48 participants. It commenced dosing in August 2024, and topline results are expected in Q3 2025. The primary endpoint is the proportion of patients who can discontinue active vitamin D and reduce calcium supplements to ≤600 mg/day while maintaining normal calcium levels. Secondary endpoints include safety, pharmacokinetics, pharmacodynamics, and quality of life. An extension study will follow for participants completing the 12-week treatment.